Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

Trial Details

NCT ID

NCT06832267

Phase

NA

Sponsor

Zhejiang Cancer Hospital

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• Patients voluntarily joined the study, signed the informed consent, and had good compliance;
• Patients with 18 Years to 75 Years(at the time of signing the informed consent); Eastern Cooperative Oncology Group Performance Status (ECOG-PS) sc…
• Patients with histopathologically confirmed newly diagnosed primary central nervous system diffuse large B-cell lymphoma, and there were intracrani…
• Patients who have not received any systemic therapy, except those who use hormones to control complications

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.